Watch NVNO. Know when insiders buy.
One email the day a filing lands. Free.
NVNO
enVVeno Medical Corp
8.96
−0.09 −0.99%
USD · close Sep 23
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $6.1MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$15.7MNET CASH —52W 8.67 – 34.09SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3.8M | −$3.6M | — | -5.37 | −$3.5M | — | — | Jul 30 |
| Q1 2026 · Mar 31 | — | — | — | −$4.1M | −$3.8M | — | -5.89 | −$3.2M | — | — | May 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$4M | −$3.7M | — | -32.28 | −$3.4M | $0 | −$3.4M | Mar 26 |
| Q3 2025 · Sep 30 | — | — | — | −$4.9M | −$4.5M | — | -0.23 | −$4.4M | $0 | −$4.4M | Oct 30 |
| Q2 2025 · Jun 30 | — | — | — | −$7M | −$6.7M | — | -11.52 | −$3.7M | — | — | Jul 30 |
| Q1 2025 · Mar 31 | — | — | — | −$5M | −$4.5M | — | -7.75 | −$4M | — | — | May 6 |
| Q4 2024 · Dec 31derived | — | — | — | −$6.7M | −$6.2M | — | -43.56 | −$5.1M | $4K | −$5.1M | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | −$6.2M | −$5.6M | — | -0.35 | −$4.3M | $9K | −$4.3M | Oct 30 |
| Q2 2024 · Jun 30 | — | — | — | −$5.5M | −$5M | — | -0.31 | −$3.9M | $14K | −$3.9M | Jul 31 |
| Q1 2024 · Mar 31 | — | — | — | −$5.5M | −$5M | — | -0.31 | −$3.5M | $10K | −$3.6M | Apr 30 |
| Q4 2023 · Dec 31derived | — | — | — | −$6.3M | −$5.6M | — | -0.32 | −$5M | $4K | −$5M | Feb 28 |
| Q3 2023 · Sep 30 | — | — | — | −$5.3M | −$5M | — | -0.45 | −$4.2M | $3K | −$4.2M | Oct 31 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$20.9M | −$19.5M | — | -33.06 | −$15.6M | $5K | −$15.6M | — | — |
| FY2024 · to Dec 31 | — | — | −$23.8M | −$21.8M | — | -44.53 | −$16.8M | $37K | −$16.9M | — | — |
| FY2023 · to Dec 31 | — | — | −$25.2M | −$23.5M | — | -1.91 | −$18.9M | $33K | −$18.9M | — | — |
| FY2022 · to Dec 31 | — | — | −$24.9M | −$24.7M | — | -2.20 | −$15.6M | $115K | −$15.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$16.9M | −$16.5M | — | -1.90 | −$11.8M | $368K | −$12.2M | — | — |
| FY2020 · to Dec 31 | — | — | −$9.1M | −$9.1M | — | -7.54 | −$7.7M | $180K | −$7.9M | — | — |
Every number comes from enVVeno Medical Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.